NCT02731690终止2 期
A Phase 2 Open-label Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy (HIBM)) Patients With Severe Ambulatory Impairment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 42
- 试验地点
- 5
- 主要终点
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
研究概览
简要总结
The primary objective of this Phase 2 study is to evaluate the safety of open-label 6 g/day Ace-ER in GNEM participants with severe ambulatory impairment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged ≥ 18 years old
- •Willing and able to provide written, signed informed consent after the nature of the study has been explained, and before any research-related procedures are conducted
- •Have a documented diagnosis of GNEM, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/N-acetylmannosamine kinase (MNK) enzyme (genotyping will not be conducted in this study).
- •Should meet the criteria for severe ambulatory impairment defined below:
- •Unable to rise from a seated position to standing without help from another person, assistive device(s), stationary object, or other support AND
- •Unable to walk without the assistance of another person OR if able to walk (use of assistive device(s) permitted), requires at least 2 minutes to walk 40 meters (one full lap of the 6-minute walk test [6MWT] course) AND
- •Use of wheelchair or scooter for activities outside of the home or unable to leave the home independently
- •Willing and able to comply with all study procedures
- •Participants of child-bearing potential or with partners of child-bearing potential who have not undergone a bilateral salpingo-oophorectomy and are sexually active must consent to use highly effective method of contraception as determined by the site investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical double-barrier methods, surgical hysterectomy, vasectomy, tubal ligation or true abstinence (when this is in line with the preferred and usual lifestyle of the subject) which means not having sex because the subject chooses not to), from the period following the signing of the informed consent through 30 days after last dose of study drug
- •Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, have had tubal ligation at least one year prior to Screening, or who have had a total hysterectomy or bilateral salpingo-oophorectomy
排除标准
- •Ingestion of N-acetyl-D-mannosamine (ManNAc), SA, or related metabolites; intravenous immunoglobulin (IVIG); or anything that can be metabolized to produce SA in the body within 60 days prior to the Screening Visit
- •Prior participation in a clinical trial involving treatment with Ace-ER/placebo and/or Sialic Acid immediate release (SA-IR) in the past year
- •Has had any hypersensitivity to aceneuramic acid or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects
- •Has serum transaminase (i.e. aspartate aminotransferase [AST] or gamma-glutamyl transpeptidase [GGT]) levels greater than 3X the upper limit of normal (ULN) for age/gender, or serum creatinine of greater than 2X ULN at Screening
- •Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study
- •Use of any investigational product or investigational medical device within 30 days prior to Screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments
- •Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study
- •Has a concurrent disease, active suicidal ideation, or other condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety
研究组 & 干预措施
Open Label UX001, 6g/day
Experimental
干预措施: Aceneuramic Acid Extended-Release (Drug)
结局指标
主要结局
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
时间窗: 48 Weeks (plus 30 [+5] days for participants not enrolling in extension study)
An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. An SAE or serious suspected adverse reaction is an AE or suspected adverse reaction that at any dose, in the view of either the Investigator or Ultragenyx, results in any of the following outcomes: death; a life-threatening AE; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or disability (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect. TEAEs were defined as any AE that occurred after the first dose of study drug.
次要结局
- Number of Participants Taking Prior and Concomitant Medications(48 weeks)
- Number of Participants With Clinically Significant Changes From Baseline In Physical Examinations(48 weeks)
- Number of Participants With Clinically Significant Changes From Baseline In Vital Signs(48 weeks)
- Number of Participants With Clinically Significant Changes From Baseline In Clinical Laboratory Results(48 weeks)
- Number of Participants With Overall Suicidal Behaviors and/or Ideation at Baseline and Post-Baseline(48 weeks)
- Change From Baseline in GNEM-FAS Expanded Version Mobility Domain Subscale Scores Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in GNEM-FAS Expanded Version Upper Extremity Domain Subscale Scores Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in HHD Raw Strength (Wrist Extensors) Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in HHD Muscle Strength in Knee Extensors Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in HHD Raw Strength (Key Pinch) Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in GNEM-FAS Expanded Version Self-Care Domain Subscale Scores Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in GNEM-FAS Expanded Version Total Scores Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in HHD Raw Strength (Grip) Over Time(Baseline, Weeks 12, 24, 36, and 48)
- Change From Baseline in HHD Raw Strength (Shoulder Abductors) Over Time(Baseline, Weeks 12, 24, 36, and 48)
研究者
研究点 (5)
Loading locations...
相似试验
终止
1 期
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Relapsed/Refractory Peripheral T-cell LymphomaNCT05403450Taiho Oncology, Inc.33
进行中（未招募）
2 期
Study of Human Bone Marrow Mesenchymal Stem Cells in APAPAutoimmune Pulmonary Alveolar ProteinosisNCT06111846Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.10
招募中
2 期
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)Pulmonary Arterial HypertensionNCT05587712Merck Sharp & Dohme LLC42
已完成
1 期
Low-Dose Ketamine in Children With ADNP SyndromeADNP SyndromeNCT04388774Alexander Kolevzon10
终止
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological MalignanciesAdvanced Nonhematological NeoplasmsNCT03370302Calithera Biosciences, Inc28